ArticleScientific reports2026
Structural characteristics and evolutionary trajectories of knowledge recombination in the field of AI-driven drug discovery.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The rapid evolution of artificial intelligence (AI) and its profound integration with the pharmaceutical industry essentially constitute a process of knowledge recombination. Yet, empirical evidence systematically characterizing the structural and evolutionary dynamics of this phenomenon in AI-driven drug discovery remains scarce. Utilizing 494 granted invention patents from Chinese AI pharmaceutical firms (2011-2024), this study establishes a multi-method framework-integrating IPC co-occurrence networks, semantic similarity, LDA topic modelling, and longitudinal sliding-window analysis-to systematically characterize this cross-domain recombination. Structurally, the network exhibits a "sparse yet concentrated" topology. Bioinformatics (G16B) emerges as the critical bridging hub, facilitating distant recombination characterized by high combinatorial intensity but low cognitive similarity. Longitudinally, the network's evolution reveals a "temporal lag" in knowledge integration, marked by declining network density alongside a rising average degree. The technological dominance transitioned progressively from traditional pharmaceuticals (A61K) to computing (G06F), and ultimately to bioinformatics (G16B) and multidisciplinary integration. These findings offer an empirical lens into the micro-level dynamics of interdisciplinary knowledge convergence, providing preliminary insights that may inform capability development and innovation policymaking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.